Rein Therapeutics, Inc. Operating Income Loss

• Rein Therapeutics, Inc. showed an increase of +22.2% in Operating Income Loss from 2024 to 2025.
• This data is from Rein Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2015 to 2025), Rein Therapeutics, Inc.'s Operating Income Loss has declined by 292.8%.
• Historical annual values: Fiscal year 2025: -$50.63 million | Fiscal year 2024: -$65.11 million | Fiscal year 2023: -$16.28 million | Fiscal year 2022: -$27.65 million | Fiscal year 2021: -$26.61 million | Fiscal year 2020: -$20.50 million | Fiscal year 2019: -$29.96 million | Fiscal year 2018: -$31.90 million | Fiscal year 2017: -$23.01 million | Fiscal year 2016: -$18.17 million | Fiscal year 2015: -$12.89 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026